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Abstract. Integrin-associated protein (IAP/CD47) is 
physically associated with the e~v133 vitronectin (Vn) re- 
ceptor and a functionally and immunologically related 
integrin on neutrophils (PMN) and monocytes. Anti- 
IAP antibodies inhibit multiple phagocyte functions, in- 
cluding Arg-Gly-Asp (RGD)-initiated activation of 
phagocytosis, chemotaxis, and respiratory burst; PMN 
adhesion to entactin; and PMN transendothelial and 
transepithelial migration at a step subsequent to tight 
intercellular adhesion. Anti-lAP antibodies also inhibit 
binding of Vn-coated particles to many cells expressing 
av[33. However, prior studies with anti-lAP did not di- 
rectly address IAP function because they could not dis- 
tinguish between IAP blockade and antibody-induced 
signaling effects on cells. To better determine the func- 
tion of lAP, we have characterized and used an IAP- 
deficient human cell line. Despite expressing av inte- 
grins, these cells do not bind Vn-coated particles unless 
transfected with IAP expression constructs. Increasing 
the level of av[33 expression or increasing Vn density on 
the particle does not overcome the requirement for 
IAP. All known splice variants of IAP restore Vn 
particle binding equivalently. Indeed, the membrane- 
anchored IAP Ig variable domain suffices to mediate 
Vn particle binding in this system, while the multiply 
membrane-spanning and cytoplasmic domains are dis- 
pensable. In all cases, adhesion to a Vn-coated surface 
and fibronectin particle binding through e~5131 fibronec- 
tin receptors are independent of IAP expression. These 
data demonstrate that some av integrin ligand-binding 
functions are IAP independent, whereas others require 
lAP, presumably through direct physical interaction 
between its Ig domain and the integrin. 
I 
NTE6RINS are heterodimeric cell surface receptors that 
mediate binding to other cells and to ligands in the ex- 
tracellular matrix. Integrin-dependent ligand binding 
and clustering-induced signal transduction lead to changes 
in cell morphology and activation state. Conversely, sig- 
nals inside the cell can result in changes in integrin ligand 
affinity and  avidity.  One  of the  proteins  implicated  in 
these  regulatory  events  is  integrin-associated  protein 
(IAP). 1 
IAP is a unique Ig family member with an amino-termi- 
nal Ig variable (IgV) domain, a multiply membrane-span- 
ning domain, and a short alternatively spliced carboxy-ter- 
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minal cytoplasmic tail (Lindberg et al., 1993; Reinhold et al., 
1995). lAP is identical to OA-3, an ovarian carcinoma an- 
tigen, and to CD47, an erythrocyte membrane protein de- 
creased in Rhnun disease (Campbell et al., 1992; Lindberg 
et al., 1994; Mawby et al., 1994). Since lAP is ubiquitously 
expressed (Brown et al., 1990; Rosales et al.,  1992; Rein- 
hold et al., 1995), its function has been inferred from the 
effect of antibody inhibition, mainly in myeloid and endo- 
thelial ceils. 
lAP was first identified as the target of antibodies that 
block  extracellular matrix-induced activation of neutro- 
phils  (PMN)  and monocytes (Brown et al.,  1990).  Anti- 
IAP mAbs also inhibit PMN transendothelial migration, 
PMN and endothelial cell chemotaxis to RGD-containing 
proteins, and PMN  adhesion to entactin (Cooper et  al., 
1995; Senior et al., 1992). In addition, anti-lAP mAbs in- 
hibit  an  increase  in  intracellular  calcium  concentration 
seen when endothelial cells spread on vitronectin (Vn) in 
an  e~v-dependent  manner (Schwartz  et  al.,  1993).  These 
studies all suggest that IAP interacts functionally with the 
integrin Otv[33, a hypothesis supported by physical associa- 
tion of the two molecules (Brown et al., 1990). Moreover, 
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to ~v~3 integrin on a variety of cells in addition to myeloid 
and endothelial cells (Lindberg et al., 1993). 
Studies  on  the  mechanisms by which  IAP cooperates 
with ~v[~3 or by which anti-IAP mAb inhibit various %133 
functions have been hampered by the ubiquity of IAP on 
tissue-culture  cells.  We have used  an IAP-deficient ova- 
rian carcinoma cell line, OV10, to better understand IAP- 
avl33 cooperation.  Although  adhesion  of these  cells to  a 
Vn-coated  surface  is  normal,  they  bind  Vn-opsonized 
beads only if they are made to express lAP by transfec- 
tion. We show that Vn-bead binding is IAP and integrin 
dependent  and correlates with  the level of both integrin 
and  IAP expression.  We also demonstrate  that  the  IAP 
IgV domain is sufficient for this function. As OVI0 adhe- 
sion to Vn on a surface is unaffected by expression of IAP, 
our data demonstrate a clear distinction between two dif- 
ferent  functions  of  c~v  integrins:  binding  of  Vn-beads, 
which is IAP dependent, and adhesion to a Vn-coated sur- 
face, which is IAP independent. 
Materials and Methods 
Chemicals, Reagents, and Antibodies 
All reagents were of the highest grade commercially available and pur- 
chased from Sigma Chemical Co. (St. Louis, MO), unless otherwise indi- 
cated. PBS and HBSS were purchased as 10X stocks from Life Technolo- 
gies/GIBCO BRL (Gaithersburg, MD) or BioWhittaker, Inc. (Walkersville, 
MD). Negative control mAb 6F2, anti-133 mAb 7G2, and anti-IAP mAbs 
B6H12 and 2D3 are all mouse IgG1 mAbs and have been described previ- 
ously (Gresham et al., 1989; Brown et al., 1990). None of these mAbs bind 
the corresponding routine antigens. Anti-av mAb L230 (Weinacker et al., 
1994) was kindly provided by Dr. Dean Sheppard (University of Califor- 
nia at San Francisco), and anti-LIBS1 (Frelinger et al., 1990)  was kindly 
provided by Dr. Mark Ginsberg (The Scripps Research Institute, La Jolla, 
CA). Control lgGl mAb MOPC21 was from Organon-Teknika (Durham, 
NC).  Anti-J31 mAb  P4CI0  (IgGl)  and  anti-av[3s  rnAb  P1F6  (IgGl) 
(Wayner et al., 1991),  as well as rabbit polyclonal anti-human vitronectin 
receptor, were from Life Technologies/GIBCO BRL. Vn was purchased 
from  Life  Technologies/GIBCO  BRL  and  Calbiochem-Novabiochem 
Corp.  (La Jolla, CA). Fluorescinated anti-CD4-IgVt mAb OKT4A was 
purchased from Ortho Diagnostics (Raritan, NJ). 
Tissue Culture 
OVM1 and OV10 were maintained in Iscove's modified Dulbecco's me- 
dium (IMDM)  (Life  Technologies/GfBCO BRL)  with  10%  FCS  (Hy- 
clone Laboratories, Logan, UT) and 50 ixg/ml gentamicin. Transfectants 
based on pRC/RSV or pIAP58 (Invitrogen, San Diego, CA) (Lindberg et 
al., 1993) were isolated and maintained in 400 txg/ml geneticin/G418 (Life 
Technologies/GIBCO BRL). Those based on pREP10 (Invitrogen) were 
selected in 200 Ixg/ml hygromycin (Boehringer Mannheim Biochemicals, 
Indianapolis, IN); those based on pSRuEN (a kind gift of Andrey Shaw, 
Washington University, St. Louis, MO) were selected in 800 ixg/ml geneti- 
cin. Double transfectants were maintained in medium with 100 Ixg/ml hy- 
gromycin and 400 p.g/ml  geneticin. For vitronectin bead binding assays, 
cells were seeded at 20,000 cells per well into glass 8-chambered slides 
(LabTek; Nunc, Naperville, IL) in 250 Ixl RPMI (BioWhittaker, Inc.) with 
10% FCS, 10 mM Hepes, and selective antibiotics at the concentrations 
stated above. 
Flow Cytometry and Cell Sorting 
Cells were removed from subconfluent tissue-culture flasks with PBS--2 
mM EDTA, washed twice in complete medium, and counted. 1-3 million 
cells were resuspended in 25 ~l complete medium with 1-3 Ixg antibody 
(saturating amounts) and incubated on ice for 30 rain. Cells were washed 
and incubated with 50 ~1 complete medium with  1 ~l goat anti-mouse 
lgG-FITC  (F-7506;  Sigma Chemical Co.),  and then incubated  an addi- 
tiona130 min. After a wash, cells were analyzed on a flow cytometer (Ep- 
ics/XL; Coulter Electronics, Inc., Hialeah, FL). For cell sorting, 15 million 
cells were stained with proportionately larger amounts of medium and an- 
tibody, resuspended at 5 million cells per ml, and sorted on a fluorescence- 
activated cell sorter (Epics 743; Coulter Electronics, Inc.). 
Selection of an IAP-deficient Cell Line 
The  ovarian  carcinoma  line  OVM1,  kindly  provided  by  Dr.  Stimson 
(Strathclyde University, Glasgow, UK), was described as CD47 deficient 
by Campbell et al. (1992). The cells we obtained contained a small propor- 
tion (0.5-1%) of IAP-positive cells. Therefore, we cloned this cell line and 
selected numerous IAP-deficient clones from it.  After tests of transfect- 
ability, the clone OVl0 was chosen for further study. OV10 is IAP defi- 
cient by FACS  ® and immunoprecipitation with all our IAP mAbs, negative 
by immunoprecipitation with polyclonal rabbit anti-IAP carboxy-terminal 
peptide antisera (Lindberg ct al., 1993),  and negative for IAP mRNA by 
Northern  blot  and  reverse-transcriptase PCR  assays (not  shown).  We 
have been unable to detect spontaneous lAP-positive cells in OV10 popu- 
lations. OVI0 express a small amount of avl33, a moderate amount of av!35 
(Table I), and a large amount of %131 (not shown). 
IAP Expression  Constructs and Transfectants 
IAP alternative splice variants are referred to as IAP-1 through IAP-4 in 
order  of increasing cytoplasmic tail  length (Reinhold et al.,  1995).  The 
pRC/RSV-based vector pIAP58 and the plAP58-derived expression con- 
structs plAP45  (IAP-2),  plAP71  (IAP-1),  and pIAP83  (mIAP; murine 
IAP-2) have been described previously (Lindberg et al., 1993). The IAP-4 
expression construct pIAP120 was constructed in analogy with plAP71, 
except that the 3'-portion of the cDNA was derived from an IAP-4 clone. 
The  3'-fragment of the IAP-3  expression construct pIAP131  was con- 
structed from the IAP-4 version by PCR-mediated deletion of the 3'-end 
of the coding sequence, to correspond to the published IAP-3 sequence 
(Lindberg et al., 1993; Campbell et al., 1992; Reinhold et al., 1995).  The 
IAP coding sequence of all constructs has been verified by dideoxynucle- 
otide chain-termination sequencing (Sanger et al., 1977).  The constructs 
were transfected into OV10 using the lipofectin method (Life Technolo- 
gies/GIBCO BRL). Clones were isolated by limiting dilution 24 h  after 
transfection. Several clones of the vector and IAP-2 transfectants were as- 
sayed with similar results. In some cases, clones were FACS  ® sorted to re- 
move populations of lower expression. The clones presented in this study 
are 58A2 (vector), 71E3 (lAP-I), 45B10 (lAP-2), 131G7 (IAP-3), 120B9 
(IAP-4), and 83E7 (mlAP). 
The  IAP-glycosylphosphatidylinositol (GPI)  construct plAP148  was 
constructed by cloning the lAP 5'-end up to and including the IgV domain 
as a  XbaI-PvulI fragment and a  PvuII-HindllI fragment encoding the 
human decay-accelerating factor (DAF) GPI signal (Medof et al., 1987) 
(kindly  provided  by  Dr.  Douglas  Lublin,  Washington University,  St. 
Louis, MO) into XbaI-HindlIl-digested plAP58 vector. The fragment en- 
coding the GPI signal was generated by PCR using the following oligonu- 
cleotides: AACCCTGCAGCTGGCATGAAACAACCCCA  and CAA- 
TGAAAGCTrCCTAAATGAAGAG. Conversely, the sequence coding 
for  the  IAP-2  membrane and  cytoplasmic domains was  isolated  from 
plAP70 (Lindberg et al., 1993) and fused with a PCR-generated Hindlll- 
PvulI fragment of the 5'-end of human CD4 (kindly provided by Dr. An- 
drey Shaw) up to and including the first IgV domain, yielding the plasmid 
plAP147.  The  oligonucleotides used were:  TGGTCTAGATGTCCCT- 
ACTGCTCAGCC and GTCAATCCGCTGCAGCTGAATTGCACCTC- 
CTC. Transfectant clones were generated as described above. The clones 
used in this study were 148A10T (IAP-GPI) and 147E9 (CD4-1AP). To 
verify results obtained with IAP-GPI, two additional independent trans- 
fectants (148C11 and 148D12) were analyzed. 
For higher IAP expression, the insert from plAP45 (IAP-2) was cloned 
as  an  XhoI-XbaI  fragment  into  the  monocistronic vector  pBSRtxEN 
(kindly provided by Dr. Andrey Shaw), yielding plAP315. Also, a construct 
encoding the IAP-IgV domain linked to a single membrane-spanning  seg- 
ment was made in  the following manner: oligonucleotides CCTGGG- 
GCGGATCCACCAAGGGCCTCTGCC  and ACTGTCTGCCATCTA- 
GAGCGTCCTCGCCAG were used in PCR on a CD16-CD7-syk construct 
(Kolanus et al., 1993)  (kindly provided by Dr. Brian Seed, Massachusetts 
General Hospital, Boston, MA), yielding the CD7  membrane-spanning 
segment as  a  BamHI-Xbal  fragment.  This was  fused  with  an  Xhol- 
BamHI fragment of lAP cDNA (obtained by PCR with oligonucleotides 
CGCTCGAGAAACGATGTGGCCCCTGGTAG and TCAT'VI'GGAT- 
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into pBSRc~EN, yielding pIAP323. In both cases, a single round of FACS  ® 
sorting yielded a population with high expression in a narrow distribution. 
These  populations were designated  IAP-2(hi)  (plAP315)  and  IAP-TM 
(plAP323). 
To  obtain  OV10  transfectants with increased  expression of integrin 
Otv[~3, a  ~3 expression plasmid was constructed by ligating  the human inte- 
grin 133 cDNA as an Xbal fragment into NheI-digested pREP10 (Invitro- 
gen), yielding  pIAP164.  Transfecting this construct into OV10 with or 
without a 20-fold  excess of pCDM8-av (Loftus et al., 1990), and selecting 
for hygromycin resistance, resulted in equivalent average levels  of av133 
expression with a corresponding increase in surface expression of C~v (as 
assayed by FACS  ® with mAbs AP3 and L230; Table I). This suggests that 
13  chain  synthesis limits  av133 expression. One  clone  of pIAP164-trans- 
fected OV10 (OV10/164-10)  was chosen and transfected in a second step 
with previously described IAP constructs, followed by geneticin selection 
and  cloning.  The  transfectant  clones  used  are:  133/vector (pIAP164+ 
plAP58B3),  133/IAP-2 (plAP164+45S2),  and  133/IAP-GPI  (plAP164+ 
plAP148C2), to yield cells expressing high amounts of ctv~3 without lAP, 
with wild-type  IAP, or with the lAP IgV domain on a GPI anchor, respec- 
tively. 
Bead Binding 
Confluent monolayers of OV10 transfectants were removed with trypsin- 
EDTA, washed in complete medium, and resuspended at 20,000 cells per 
ml  in  RPMI-based  selection  media  (RPMI  with  10%  FCS,  400  p,g/ml 
G418, and/or 100 ~xg/ml hygromycin, depending on the transfectant). Cell 
suspensions were added  to glass 8-chamber LabTek slides  and cultured 
for 24 h at 37°C in 5% CO2. Vn-bead binding was optimal in a buffer of 
HBSS containing 10 mM Hepes, 0. 1 mM MnCI2, and 1% human serum al- 
bumin (HSA) (bead-binding buffer), which was used for all studies. Ad- 
herent cells were washed twice with buffer and incubated with antibodies 
in 250 Ixl buffer for 20 min at room temperature. The antibodies used were 
MOPC21,  anti-lAP mAb 2D3 and  B6H12  (Brown et al.,  1990), anti-133 
mAb 7G2 (Gresham et al.,  1989; Brown et al., 1990), and anti-C~v135 mAb 
P1F6 (Wayner et al., 1991) all at 10 Ixg per well, as well as anti-131 P4CI0 
(1:50 dilution of ascites).  After incubation with the antibodies, the adher- 
ent cells were washed twice, and 250 Ixl buffer was added to each well. Vn- 
and HSA-coated beads were made exactly  as described (Lindberg et al., 
1993), except that the source of the Vn was Life Technologies/GIBCO 
BRL or Calbiochem-Novabiochem Corp. The cells  were incubated with 
either 20 Ixl Vn- or HSA-coated beads. For 133 transfectants in Fig. 5, A 
and C, the volume of beads was reduced to 5 ixl to facilitate  counting of at- 
tached beads. After 1 h at 37°C, unbound beads were washed away, and 
the  number of beads bound was assessed by fluorescence microscopy. 
Binding was quantitated  as an attachment index,  the  number of beads 
bound per 100 cells. 
Assay for Ligand-induced Binding Sites 
OV10 transfectants were harvested in PBS-2 mM EDTA, washed twice in 
HBSS without divalent cations, and resuspended to 2 million  cells per ml 
in bead-binding buffer or in bead-binding buffer with 5 mM MgC12 rather 
than 0. 1 mM MnCl  2, Human IgG (500 i.Lg/ml) was used to further reduce 
nonspecific binding. 100-~1 aliquots were incubated 30 min at room tem- 
perature with anti-LIBS1 (10 Iz/ml) (Frelinger et al., 1990) and KYAVT- 
GRGDS at varying concentrations. After two washes, cells were stained 
with FITC-labeled secondary antibody and analyzed by flow cytometry. 
Adhesion Assays 
Flat-bottom 96-well microtiter plates (Immulon2; Dynatech Laboratories, 
Inc., Chantilly,  VA) were coated overnight (4°C) with matrix protein in 
PBS, blocked for 1 h or more with PBS/1%  HSA at room temperature, 
and washed twice  with HBSS without divalent cations (HBSS--) before 
cell  addition.  Subconfluent monolayers were removed with PBS/5  mM 
EDTA twice in IMDM (without FCS) and incubated at 3 million cells per 
ml for 15  min (37°C)  in IMDM-1% BSA containing 3 p.M calcein-AM 
(Molecular Probes, Eugene, OR). Ceils were washed twice in HBSS--, fol- 
lowed by resuspension in bead-binding buffer (HBSS/0.  1 mM MnCIJ1% 
HSA) at 1 million cells per ml. Cells were diluted 1:2 in buffer containing 
the appropriate blocking mAb, preincubated for 10 min at room tempera- 
ture, and added to the microtiter plates at 100 ~1 per well  (50,000 cells). 
After 60 rain at 37°C, fluorescence was read on a plate reader (excitation 
485 rim, emission 530 nm; Cytofluor 2300; Millipore  Corp., Bedford, MA) 
before and after two washes with adhesion buffer. Data are given as the 
fraction of total fluorescence that was retained through the washes. 
Maximal adhesion obtained with any substrate was ~80%, with back- 
ground from blocked wells <2%. 
Phosphoinositide Phospholipase C Treatment 
Confluent monolayers of cells were removed with trypsin-EDTA, washed 
in complete IMDM with 10 mM EDTA, and resuspended in the same me- 
dium to 3 million cells per ml. 0.5-ml aliquots were incubated with or with- 
out the addition of 0.1  U of phosphoinositide phospholipase C (PI-PLC) 
(Boehringer Mannheim Biochemicals) for 1 h at 37°C. Volumes of 0.1 ml 
were pelleted in microtiter plates, washed, and processed for flow cytome- 
try after staining with negative control mAb 6F2 or anti-IAP mAbs 2D3 
or 1F7. Both anti-IAP mAbs gave identical  results. 
IAP-fl3 Coimmunoprecipitation 
Cells  were grown to subconfluence, harvested by scraping, and washed 
three times in HBSS--.  40 million  cells (routinely >98% intact by trypan 
blue exclusion) were lysed in 1 ml 0.25 M sucrose/50 mM Hepes (pH 7.4)/ 
100 mM octylglucoside  with protease inhibitors (5 mM iodoacetamide, 1 
mM PMSF,  50 Ixg/ml aprotinin, 50 p,g/ml leupeptin) by rotation for 2 h at 
4°C. Lysates were cleared  by a 30-min  centrifugation (15,000 g) at 4°C. 
Equal fractions of the  lysate were rotated  at  4°C with 50  pA  anti-IAP 
(2D3), anti-133 (7G2), or anti-err135 (P1F6)  Sepharose. Sepharose was pre- 
pared  by  binding  2  mg  mAb  to  1  ml  cyanogen  bromide-activated 
Sepharose (Pharmacia, Uppsala, Sweden) as recommended by the manu- 
facturer. The affinity  Sepharose was washed with 10 mM Tris-HC1  (pH 
8.0)/0.1% Tween-20 and 150 mM NaCI. Bound protein was eluted by incu- 
bation for 10 min at 65°C with nonreducing SDS sample buffer (Laemmli, 
1970). Equivalent fractions of the  total sample were electophoresed on 
7.5%  SDS-PAGE, transferred to Immobilon P (Millipore  Corp.), and re- 
acted with anti-133 mAb 7G2.  Detection was by enhanced chemilumines- 
ence according to the manufacturer's recommendations (ECL; Amersham 
Corp., Arlington Heights, IL). 
Results 
Vn-Bead Binding Is Deficient in OVIO, But Can Be 
Restored by lAP Transfection 
To analyze the structure-function relationships in IAP, we 
isolated an IAP-deficient clone, OV10, from the ovarian 
carcinoma cell line OVM1  (see Materials and Methods). 
OV10 cells express large amounts of [~1 and et5 (not shown), a 
moderate amount of etv and 135, and a small amount of [33 
(Table I). When assayed for Vn-bead binding, OV10 cells 
showed attachment  indices only marginally above those 
seen with beads coated with HSA. However, transfectants 
expressing IAP-2 (Fig. 1), the predominant form of IAP in 
myeloid cells, showed a  markedly enhanced  capacity to 
bind Vn-beads (Fig. 2 A). Binding was increased with in- 
creasing Vn density on the bead, but it remained IAP de- 
pendent up  to saturating  Vn  concentrations (~12.5  ~g/ 
ml). The IAP-mediated enhancement of Vn-bead binding 
was completely reversed by the functional anti-IAP mAb 
B6H12 (Fig. 2 A). The IAP dependence was Vn specific, 
as binding to fibronectin (Fn)-opsonized beads was inde- 
pendent of IAP and unaffected by the presence of anti- 
lAP mAb B6H12 (Fig. 2 B). Vn-bead binding was entirely 
dependent on Ctv[33 and Ctv135, as shown by its sensitivity to 
anti-133 mAb 7G2 (Fig. 2 D) and anti-ctv[35 mAb P1F6 (Fig. 
2 C), and was independent of [~1 integrins, as shown by re- 
sistance to inhibition by anti-131 mAb P4C10 (Fig. 2 C). In 
contrast, Fn-bead binding was almost completely inhibited 
by P4C10,  but  unaffected by 7G2  (Fig.  2  B).  Anti-IAP 
mAb 2D3 binds lAP with similar affinity as B6H12, but it 
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Mean fluorescence* 
Antibody Antigen 
6F2  B6Hl2  PIF6  L230  OKT4A  W6/32 
Name  s  Plasmid  ~  (control)  IAP  AP3  c~[35  av  CD4  MHC 
--  --  0.50 ±  0.06  0.53 ±  0.04  0.64 ±  0.05  1.92 ±  0.29  3,42 ±  0.14  0.99 ±  0.11  12.17 ±  0.70 
vector  plAP58  0.73 ±  0.05  0.77 ±  0.01  0.83 ±  0.01  2.12 ±  0.56  3.99 ±  0.55  ND  30.15 ±  5.13 
IAP-1  plAP71  0.64 --- 0.07  1.71  ±  0.19  0.66 ±  0.05  2.14 -+ 0.47  3.16 ±  0.28  ND  13.77 ±  2.23 
IAP-2  plAP45  0.74 ±  0.05  7.97 -+ 0.54  0.90 ±  0.08  3.02 ±  0.69  4.69 ±  0.28  ND  22.80 -+ 4.16 
IAP-3  plAPt31  0.61  +- 0.04  2.82 ±  0.24  0.64 -+ 0.04  2.04 ±  0.49  3.17 ±  0.31  ND  11.84 -+ 2.39 
IAP-4  plAP120  0.79 ±  0.13  9.40 ±  0.99  0.77 ±  0.04  2.52 ±  0.26  4.90 ±  0.82  ND  23.50 ±  5.87 
IAP-CD4  plAP147  0.75 ±  0.00  0.68 -+ 0.02  0.82 ±  0.03  2.18 ±  0.07  3.92 ±  0.12  3.10 ±  0.08  27.75 ±  0.39 
IAP-GPI  plAP148  0.66 ±  0.03  7.64 ±  0.30  0.73 ±  0.06  2.49 ±  0.40  3.57 ±  0.21  ND  20.80 ±  4.70 
IAP-2(hi)  plAP315  0.62 ±  0.07  36.93 ±  0.81  0.66 ±  0.05  2.32 ±  0.15  4.45 ±  0.16  ND  20.03 -+  1.47 
IAP-TM  plAP323  0.57 ±  0.05  11.68 ±  1,42  0.64 ±  0.04  2.72 ±  0.12  3.49 ±  0.12  ND  13.43 ±  0.80 
[33/vector  plAP164 +  58  0.78 ±  0.08  0.82 ±  0.09  4.18 ±  1.86  1.54 ±  0.24  10.42 -+ 0.36  ND  20.80 ±  4.70 
133/IAP-2  plAP164 +  45  0.80 ±  0.05  3.77 ±  0.13  7.01  ±  0.42  1.95 ±  0.32  12.53 ±  0.41  ND  17.73 ±  1.48 
[33flAP-GPI  j  plAPI64 +  148  0.70 ±  0.05  6.06 ±  0.31  4.29 ±  0.10  1.89 ±  0.36  7.70 ±  0.28  ND  20.03 ±  1.47 
*Mean and standard error from two to three determinations with saturating amounts of antibody are shown. Multiple assays throughout this study gave similar relative results. In 
all cases, the cell populations yielded narrow single peaks, except for lAP-2, IAP-GPI, and IAP-2(hi) where a small population (<10%) of low positive cells could be seen with 
anti-IAP, and [33/vector where a small population (< 10%) of ceils could be seen with slightly higher staining with AP3 and L230. The murine IAP-2 expressing clone (mlAP) was 
not assayed in this experiment. In separate experiments, integrin expression on mlAP was not different from untransfected or vector transfected OV 10 (-- and vector, respectively). 
;The name given is that used in all of the figures and the text. For the clone name, see Materials and Methods. 
~The plasmid used to transfect the OVI0 parental cell line. Where two plasmids are listed, the first plasmid was transfected into OV10, a clone selected, and this clone was then 
used as a parent of all transfectants harboring this plasmid. 
NThe IAP-GPI clone shown is 148A10. lAP expression of clone 148C 11 is similar, and that of clone 148D12 is ~  50% higher (not shown). 
MHC, major histocompatibility complex class I antigen. 
has been shown to be nonfunctional in assays of Vn-bead 
binding  and  other  IAP-dependent  integrin  functions 
(Lindberg et al., 1993).  This was also true in our transfec- 
tion  system,  where  mAb  2D3  did  not  inhibit  Vn-bead 
binding of IAP transfectants (Fig. 2 D). Vn-bead binding 
was also high  in  OV10  expressing murine  IAP, showing 
that the IAP effect on integrin function is not species spe- 
cific (Fig. 2 E). This result also verified that the effect of 
anti-IAP mAb B6H12 is specific, since this mAb has no ef- 
fect on Vn-bead binding by the murine IAP expressors. 
IAP function has been associated with C~v[33 rather than 
av[35. To determine if this was true in OV10, we tested the 
effect of anti-C~v[35 mAb P1F6 on Vn- and Fn-bead binding. 
P1F6  completely inhibited Vn-bead binding in a  manner 
similar to anti-J33 mAb 7G2 (Fig. 2 C). Surprisingly, testing 
multiple  preparations  from  several  sources,  we  consis- 
tently found inhibition of Fn-bead binding by P1F6 as well 
(Fig. 2 B). This suggests that P1F6 ligation of C~v[35 may af- 
fect  the  function  of  multiple  OV10  integrins,  perhaps 
through "integrin cross talk" (Blystone et al., 1994,  1995). 
Thus, our data indicate that expression of IAP specifically 
and markedly enhances  Vn-bead binding,  but we cannot 
determine the relative contributions of C~v[33 and av[35. 
Adhesion to a Vn-coated Surface Is lAP Independent 
To investigate the role of IAP in adhesion to a Vn-coated 
surface, we adhered different transfectants to microtiter plate 
wells coated with different concentrations of Vn (1 ng/ml 
to 10 ~g/ml) for 60 rain, using the same conditions as for 
the Vn-bead binding. Adhesion was maximal at a coating 
concentration of 100 ng/ml Vn, and only marginally above 
background at 3 ng/ml (not shown). Anti-J33 7G2 does not 
inhibit adhesion in other clearly ~XvJ33-dependent systems, 
and it failed to do so here as well. Therefore, anti-c~  v mAb 
L230 was used in combination with anti-%J35 mAb P1F6 to 
dissect integrin dependence. At a Vn concentration of 50 
ng/ml, binding was inhibited  completely by L230 and al- 
most  completely by  P1F6.  Only  minimal  differences  in 
binding  between  IAP-positive  and  lAP-negative  cells 
were seen (Fig. 3), which correlated with small differences 
in  C~vf33 and  ~vJ35 expression  (Table  I).  OV10  expressing 
high levels of [33 from transfected 133 cDNA (J33/vector and 
~3/IAP-2) maintained  significant binding in the presence 
of 10 ~g/ml anti-%J35 mAb PIF6. This suggests that bind- 
ing under  these  conditions  was mainly Uv~5 mediated  in 
the low 133 cells (vector and IAP-2) and mediated by both 
ct  v integrins in the high 133 expressors. Both in the presence 
and  absence  of  P1F6,  there  was  no  effect  of  anti-lAP 
B6H12 even at 150 p~g/ml (Fig. 3; not shown). Thus, under 
these conditions, lAP is uninvolved either in J3~ integrin- 
dependent binding of particles coated with Fn or in adhe- 
sion to a Vn-coated surface. 
The lAP Cytoplasmic Domain Is Irrelevant  for 
Vn-Bead Binding 
IAP exists as four different forms generated by alternative 
splicing that differ only in their carboxy-terminal cytoplas- 
mic extensions. These forms are called IAP-1, IAP-2, IAP-3, 
and IAP-4 (Fig. 1), in order of increasing cytoplasmic tail 
length  (Reinhold et al.,  1995).  While  IAP is ubiquitously 
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CD4-1AP 
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Figure 1.  Predicted structure of IAP variants used. Amino acids 
are shown in single-letter amino acid code or as lines. Ovals rep- 
resent membrane-spanning segments, and l) denotes Ig domains. 
IAP-derived segments are shown as solid lines, ovals, and letters 
without underlining, while other segments are shown as broken 
lines (the  CD4  IgV1  domain),  open  ovals (the  CD7  membrane 
segment),  or  underlined  letters  (sequences  derived  from  CD4, 
CD7, or created in the fusion). The GPI anchor is shown as a cir- 
cle connected  to the serine residue to which the  GPI  anchor  is 
linked.  Residues  shown  within parentheses  are  removed as the 
GPI  anchor  is  added,  lAP-l,  IAP-2,  IAP-3,  and  IAP-4  corre- 
spond to naturally occurring splice variants of lAP. The expres- 
sion of the correct tail has been verified for forms to which spe- 
cific antisera  have  been  raised  (IAP-2  and  IAP-4).  IAP-2  and 
IAP-2(hi) differ only in the level of expression and the expression 
vector used. Murine lAP (mlAP) has the murine IAP-2 tail (not 
shown). 
expressed, the alternative splicing is under strict cell type- 
specific control, leading to the almost exclusive expression 
of IAP-2  in  myeloid  cells and  endothelium,  and  virtually 
exclusive  expression  of  IAP-4  in  neuronal  tissue  (Rein- 
hold et al.,  1995).  To determine  the role of the  lAP  cyto- 
plasmic tail in Vn-bead binding, we used transfectants  ex- 
pressing  the  different  splice  forms  of  IAP  in  the  bead 
binding  assay.  As shown in Fig. 2,  C  and  D, expression  of 
any of the four forms of lAP in OV10 led to enhancement 
of Vn-bead  binding. This included  IAP-1, which  has only 
Figure  2.  Efficient  binding  of  vitronectin-coated  but  not  fi- 
bronectin-coated particles is dependent on IAP. (A) OV10 trans- 
fected  with  vector  alone  (vector)  or  an  IAP-2  expression  con- 
struct  (IAP-2)  were assayed  for Vn-bead  binding,  expressed  as 
beads bound per 100 cells (Attachment Index). Before the assay, 
cells were preincubated  for 20 min with the indicated mAbs (40 
i.tg/ml),  followed by two washes.  Vn-beads prepared in different 
concentrations of vitronectin were used.  Increasing the Vn con- 
centration increased specific binding, but binding remained IAP 
dependent  and  B6H12  inhibitable.  All binding was  sensitive to 
anti-133 mAb  7G2  (not  shown).  (B)  The  experiment  was  per- 
formed as in A, except that beads were coated with 10 ~g/ml fi- 
bronectin.  IAP expression,  anti-IAP mAbs B6H12,  and  anti-133 
mAb  7G2  were  all  without  effect  (40  i~g/ml), whereas  anti-131 
mAb P4C10 (1:50 dilution of ascites) inhibited binding. Surpris- 
ingly, anti-av135 mAb P1F6 (40 p~g/ml) inhibited binding to an ex- 
tent  comparable  to  anti-13]  mAb  P4C10  (see  text).  (C)  OV10 
transfected with vector alone (vector) or constructs encoding lAP 
alternative splice forms with successively longer cytoplasmic tails 
(lAP-l,  IAP-2,  IAP-3)  were  grown  in  Labtek  chambers,  and 
binding of Vn- or HSA-coated latex beads was assayed  as in A. 
All three  forms  of lAP conferred the Vn-bead binding  pheno- 
type, which  is sensitive to inhibition  by  anti-lAP mAb B6H12. 
Vn-bead binding was inhibited by anti-av[35 mAb P1F6, whereas 
anti-J31 mAb P4C10 was without effect. Data are mean +SEM of 
three  experiments  performed  under  identical  conditions.  (D) 
Transfectants  expressing  the  longest  form  of  IAP  (IAP-4) 
showed  enhanced  bead  binding  inhibited  by  anti-lAP  mAb 
B6H12, whereas the nonfunctional anti-IAP mAb 2D3 had no ef- 
fect.  In all cases,  Vn-bead  binding was  completely inhibited  by 
anti-133 mAb  7G2.  (E)  OV10  transfected  with  vector alone,  or 
constructs  encoding  human  IAP-2  (IAP-2)  or  murine  IAP-2 
(mlAP) were assayed for Vn-bead binding. Both human and mu- 
rine lAP mediated the enhancement  of Vn-bead binding. Anti- 
IAP mAb B6H12 does not bind murine IAP. While it inhibited 
Vn-bead  binding  mediated  by human  IAP, it had  no  effect on 
binding mediated by murine lAP. 
Lindberg et al. lntegrin-associated  Protein  13 | 7 Figure 3.  Vn adhesion is IAP independent. OV10 overexpressing 
IAP-2 and 133 (fla/IAP-2), IAP-2 alone (IAP-2), 133 alone (fl3/vec- 
tor), or neither (vector) were assayed  for adhesion to microtiter 
plate wells coated with Vn (50 ng/ml) in the presence or absence 
of various mAbs (B6H12 and 2D3 at 150 ~g/ml, L230 and P1F6 at 
40 txg/ml). Maximal adhesion was 70-80%, and background was 
0-2%. Means +  SEM for triplicate wells from a representative 
experiment are shown. Experiments varying the Vn-coating con- 
centration (1 ng/ml to 10 ixg/ml) or incubation  time (15-120 min), 
or the anti-lAP concentration (10 txg/ml to 150 ixg/ml), failed to 
show any effect of lAP on the level of adhesion. 
four  amino acids  after  the  last  hydrophobic membrane 
segment (Lindberg et  al.,  1993).  Thus, the  13-, 20-, and 
32-amino acid cytoplasmic segments of IAP-2, -3, and -4 
are  neither necessary nor inhibitory for the  lAP-depen- 
dent Vn-bead binding phenotype. 
The lAP IgV Domain on a GPI Anchor Is Sufficient to 
Mediate the lAP Effect on Vn-Bead Binding 
We next sought to determine the roles for the IAP extra- 
cellular and multiply membrane-spanning  domains in Vn- 
bead binding. For this purpose, we made a  construct en- 
coding the IAP IgV domain fused to the human DAF GPI 
anchor signal (IAP-GPI), as  well  as  the  "inverse" con- 
struct encoding the human CD4 IgV1 domain fused to the 
IAP-2 membrane and  cytoplasmic domains (CD4-IAP) 
(Fig.  1).  Clones  of  the  corresponding transfectants  ex- 
pressed the recombinant proteins (Table I). Surprisingly, 
IAP-GPI  enhanced  Vn-bead  binding, while  CD4-IAP 
failed do so (Fig. 4 A). To confirm this unexpected finding, 
two additional transfectant clones of IAP-GPI were tested 
Figure 4.  The IAP IgV domain is sufficient to mediate vitronec- 
tin bead binding. (A) Vitronectin- and HSA-coated latex particle 
binding were assayed as in Fig. 2. OV10 cells were transfected 
with vector alone (vector),  wild-type lAP (IAP-2), a construct en- 
coding the IAP IgV domain linked to a DAF GPI signal (1AP- 
GPI), or the CD4-IgV]  domain linked to the IAP-2 membrane 
and cytoplasmic domain (CD4-1AP). Surprisingly, IAP-GPI me- 
diated Vn-bead binding, suggesting  that the IAP IgV domain is 
sufficient to complement the bead binding phenotype, and that 
the membrane and cytoplasmic domains are dispensable for this 
function. Data are mean + SEM of three experiments performed 
under identical conditions. (B) Another two independent IAP- 
GPI transfectants (148D12  and 148Cll) were compared to IAP-2 
and the original IAP-GPI clone (tAP-GPI) with similar results 
(representative of two experiments). (C) OV10 clones expressing 
IAP-GPI (IAP-GP1, 148Cll,  148D12) and a control clone ex- 
pressing IAP-2 were trypsinized and incubated for 1 h at 37°C in 
complete medium with 2 mM EDTA with or without 0. 2 U/ml 
PI-PLC, as described in Materials and Methods. After the diges- 
tion, cells were washed  and stained with anti-IAP mAb 2D3 (no 
PI-PLC and 2 U/ml PI-PLC) followed by FITC-goat anti-mouse 
IgG and analysis by flow cytometry. As a negative control, un- 
treated cells were stained with mAb 6F2 (control  mAb). PI-PLC- 
treated cells gave identical reactivity with the control mAb and 
are therefore not shown.  The PI-PLC treatment completely re- 
moved surface lAP reactivity from the IAP°GPI clones, whereas 
it had no effect on wild-type lAP, showing that the clones indeed 
expressed  the expected IAP form (representative of two experi- 
ments). Data obtained using anti-IAP mAb 1F7 were identical 
(not shown). 
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Furthermore, we confirmed that IAP-GPI was in fact GPI 
linked by demonstrating that essentially all anti-lAP reac- 
tivity could be removed from the surface of IAP-GPI by 
PI-PLC, whereas expression of wild-type IAP-2 was unaf- 
fected by this enzyme (Fig. 4  C). Thus, the GPI-anchored 
IAP IgV domain  is  sufficient  for the  restoration  of Vn- 
bead binding to IAP-deficient cells. 
The lAP IgV Domain Functions Irrespective of the 
Nature of the Domain Anchoring It to the Membrane 
GPI-anchored proteins exist in specialized membrane do- 
mains in which they are associated with intracellular src ki- 
nases  (Brown,  1993).  Cross-linking of several  GPI-linked 
proteins  leads  to  kinase  activation  (Brown,  1993).  It  is 
therefore  theoretically  possible  that  the  IAP  multiply 
membrane-spanning  domain  functions  in  a  manner  that 
can be duplicated  by these  special  properties  of the  GPI 
anchor. To exclude this possibility, we generated cells ex- 
pressing  the  IAP-IgV domain  linked  to  the  single  trans- 
membrane segment of human CD7 (IAP-TM) (Fig. 1). As 
shown in Fig. 5 A, this construct enhanced Vn-bead bind- 
ing as well as IAP-2 and IAP-GPI, showing that the mem- 
brane-anchored  IAP-IgV domain suffices for this pheno- 
type,  irrespective  of the  exact  nature  of the  membrane 
anchor. 
Increases in Either lAP or avfl3 Expression Lead to 
Increased Vn-Bead Binding 
We  observed  that  the  extent  of Vn-bead  binding  corre- 
lated with the level of IAP expression regardless of splice 
form. This suggested that IAP expression was limiting to 
Vn-bead binding. To test this hypothesis, we made a  con- 
struct  encoding  IAP-2  using  a  more  efficient  promoter 
(see  Materials  and Methods).  A  transfectant  of this  con- 
struct  (IAP-2[hi])  expressed  IAP  at  significantly  higher 
levels than the control clone (IAP-2) (Table I) and bound 
Vn-beads  at  a  significantly  higher  level  than  the  IAP-2 
construct  (attachment  index  of  373  vs  181)  (Fig.  5  B). 
Thus, the extent of bead binding correlated with IAP ex- 
pression. 
It was surprising that Vn-bead binding was inhibited by 
anti-[33 mAb 7G2, even though OV10 expresses only mini- 
mal  levels  of integrin  ad33  (Table  I).  To investigate  this 
further,  and to test the  hypothesis  that  lAP dependence 
could be overcome by increased surface expression of the 
integrin,  we derived  a  series of clones with  high e~v133 ex- 
pression by transfection with [33-encoding constructs (Ma- 
terials  and  Methods).  Even  with  high  expression  of the 
a~63,  Vn-bead  binding  was  markedly  enhanced  by  IAP 
(Fig.  5  C).  Clones  overexpressing  both  the  integrin  and 
IAP (13JIAP-2) bound Vn-beads to a much greater extent 
than  even  the  1AP-2(hi)  clone  (Fig.  5  B),  although  they 
had significantly lower lAP surface expression than 1AP- 
2(hi) (3.77  +- 0.13 vs 36.93 +_ 0.81; see Table I). Thus, both 
C~v[33 expression  and lAP expression  are  limiting  for Vn- 
bead binding by OV10. In the av63-overexpressing clones, 
the membrane-anchored  IAP IgV domain alone was still 
sufficient to restore Vn-bead binding, since expression of 
IAP-GPI was as efficient as IAP-2 (Fig. 5 C; lower attach- 
ment indices in this experiment reflect the lower bead con- 
Figure 5.  Bead binding is supported by the IAP IgV domain irre- 
spective of membrane anchor and related to the level of both IAP 
and C~vt33 expression.  Vn-bead binding was assayed as in Fig. 2, us- 
ing  OV10  transfected  with  vector  alone  (vector), a  high  level 
IAP-2 expression construct (IAP-2[hi]), or a construct express- 
ing lAP IgV fused to the human CD7 transmembrane segment 
(IAP-TM).  IAP-TM mediated  enhancement  of Vn-bead bind- 
ing, showing that the nature of the membrane anchor is unimpor- 
tant (IAP membrane domain vs GPI anchor vs CD7 membrane 
segment) in this  system.  (B) Vn-bead binding was assayed with 
OV10 transfected with vector alone (vector), the clone expressing 
IAP-2 (lAP-2), a clone expressing approximately fourfold higher 
levels of IAP-2 (IAP-2[hi]), or a transfectant overexpressing both 
IAP-2 and integrin avl33 (~3/IAP-2). Attachment indices obtained 
in the presence of 40 ixg/ml anti-133 mAb 7G2 were 9, 11, 13, and 
22, respectively, and those obtained with HSA beads were 1, 2, 1, 
and 5, respectively.  Increases in lAP expression increased Vn- 
bead binding, as did increased a~133 expression. (C) A transfec- 
tant expressing high levels  of c~133 was generated  and  retrans- 
fected with vector alone (fl3/vector),  or expression constructs for 
IAP-2 ([33/IAP-2) or IAP-GPI ([33/IAP-GPI). In the presence of 
40 I~g/ml 7G2, attachment indices were 2, 5, and 5, respectively. 
With HSA beads, they were ~<2. As all these Otv~  3 overexpressors 
showed markedly enhanced binding (see B), fewer beads were 
used in the assay, to arrive at countable levels of Vn-bead binding 
(see Materials and Methods). Despite the higher level of o~v[3  3 ex- 
pression, Vn-bead binding is still IAP dependent and can be me- 
diated by the GPI-anchored IAP-IgV domain. 
centrations used in this experiment).  As with the original 
OV10  lAP  transfectants,  the  enhancement  of  Vn-bead 
binding  in  the  etv133-overexpressing  cells  was  completely 
reversed by anti-lAP mAb B6H12 and completely inhib- 
ited by anti-J33 mAb 7G2. Despite overexpression of o~vl33, 
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binding (Fig. 6). 
Induction of f13 Ligand-induced Binding Sites Is Not 
Influenced by lAP 
To determine if IAP alters the affinity state of e~v133, we de- 
termined  the  generation  of the  ligand-induced  [33 LIBS1 
epitope  by increasing concentration of peptide  KYAVT- 
GRGDS on OV10 expressing high amounts of av133 with 
or  without  IAP-2  (see  Materials  and  Methods).  Over  a 
range of 1-1,000  txM  ligand, there was clear induction of 
the  LIBS1 epitope, with  a  higher ligand sensitivity in 0.1 
mM MnCI2 than in 5 mM MgC12.  However, we observed 
no  difference  between  IAP-positive  and  IAP-negative 
cells in these experiments (not shown). 
Coimmunoprecipitation  of [33 and lAP 
The dependence of Vn-bead binding on the plasma mem- 
brane concentration of both IAP and Ctv133 suggested that 
the  relevant  binding structure  contained  both  molecules, 
as  has been  shown  previously (Brown et  al.,  1990; Zhou 
and  Brown,  1993).  Thus,  we  examined  whether  the  two 
proteins could be coprecipitated in transfected OV10 cells. 
When either IAP-2 or IAP-GPI was immunoprecipitated, 
coprecipitated  [33 could be  detected  by Western  blotting 
(Fig. 7), showing that the Ctv133 association can be mediated 
by the IAP IgV domain alone. No 133 was coprecipitated 
with Ctv135. Coprecipitated  133 was a small minority of total 
Figure 6.  Both  anti-133 and  anti-ctv135 inhibit  Vn-bead  binding 
even in av133 overexpressors. OV10 transfectants expressing high 
levels of av133 alone ([33~vector)  or IAP-2, and high levels of C~v133 
(fl3/IAP-2)  were  assayed  for  Vn-bead  binding.  Preincubation 
with anti-IAP mAb B6I-I12 inhibits  the increase in bead binding 
obtained by IAP-2 expression, whereas noninhibitory anti-lAP 
mAb 2D3 has no effect.  Both anti-133 mAb 7G2 and anti-av135 
mAb P1F6 inhibited  Vn-bead binding completely. Attachment 
indices  with HSA beads were ~<5. Absolute attachment indices 
are higher than in Fig. 5 C as a result of the use of higher amounts 
of Vn-beads (see Materials and Methods). 
Figure 7.  Both IAP-2 and IAP-GPI associate with  133 integrin. 
Cell  extracts  in  100  mM  octyl-glucoside were  prepared  from 
transfectants overexpressing etv133 and IAP-2 (lanes  1, 4, and 7), 
av133 alone, (lanes 2, 5, and 8), or av133 and IAP-GPI (lanes 3, 6, 
and 9) and immunoprecipitated with anti-ctv[35 mAb P1F6, anti- 
lAP mAb 2D3, or anti-[33 mAb 7G2. Immunoprecipitates were 
separated by nonreducing SDS-PAGE, transferred to Immobilon 
P, and immunoblotted with anti-133 mAb 7G2. Peroxidase-conju- 
gated  anti-mouse  IgG was used  as a  secondary antibody,  fol- 
lowed by detection with enhanced chemiluminesence. A reactive 
band migrating at the 133 position (~95 kD) can be seen in both 
the IAP-2 and IAP-GPI transfectants (lanes 4 and 6), but is ab- 
sent in the IAP-deficient control (lane 5). No 133 was coprecipi- 
tated with the control antibody P1F6, whereas anti-133 mAb 7G2 
could immmunoprecipitate the antigen from all three cell types. 
Thus, both IAP variants associate with 133 integrin. 
133, suggesting that the majority of both lAP and 0tv133  was 
not in a stable complex. 
Discussion 
Antibody to integrin-associated  protein  (IAP/CD47)  has 
been shown to affect a large number of cell functions asso- 
ciated with Uv133 and ~v133-1ike integrins,  such as Vn-bead 
binding, RGD activation of Fc-receptor-mediated phago- 
cytosis, chemotaxis,  and oxidative  burst,  as well as  PMN 
migration through epithelial  or endothelial  barriers  (Par- 
kos et al.,  1991,  1996; Cooper et al.,  1995; Gresham et al., 
1992; Senior et al., 1992). Because of the ubiquity of IAP 
expression, it has been difficult to determine if the effects 
of anti-lAP mAb were to inhibit IAP function, or if mAb 
binding to lAP generated a negative signal that then inhib- 
ited function. Indeed, the transfection of human IAP into 
CHO cells expressing hamster lAP made Vn-bead binding 
sensitive to the anti-human IAP mAb B6H12, raising the 
possibility that the antibody generated a signal that specif- 
ically regulated ot  v integrin function (Lindberg et al., 1993). 
In this paper, we have directly tested whether or not lAP 
is necessary for Vn-bead binding by Otv integrins. We have 
shown that a  cell line lacking IAP fails to bind Vn-beads 
and that expression of lAP on these cells confers the abil- 
ity to bind Vn-coated particles.  Increased integrin expres- 
sion led to increased binding, but failed to obviate the lAP 
requirement. Thus, the phenotype of IAP-deficient cells is 
similar  to that  of anti-lAP-treated,  IAP-expressing cells. 
The requirement for IAP does not reflect direct binding of 
Vn-beads  by IAP, since  in  all  cases  it  is  inhibited  com- 
pletely by anti-133 and Ctv135 mAbs. Expression of lAP does 
not influence 131 integrin bead binding, since ~513a integrin- 
mediated binding of Fn-beads is unaffected by the absence 
of IAP. 
In  requiring  IAP,  Vn-bead  binding  differs  from adhe- 
sion  to  a  Vn-coated  surface,  which is  lAP independent. 
Similarly,  txv-dependent  spreading  of endothelial  cells  on 
Vn is  IAP independent,  whereas  the concomitant rise  in 
intracellular  calcium  concentration  can  be  inhibited  by 
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bead  binding  and  adhesion  to  a  Fn-coated  surface  has 
been described for K562 cells, which was attributed to the 
requirement for a  high  affinity %131 in Fn-bead  binding 
(Blystone et  al.,  1994).  Possibly, lAP  is  necessary for a 
higher avidity of avl33, which might be required for Vn- 
bead binding. Whether this reflects a dependence on IAP 
for generation of high affinity e%133 or another mechanism 
for creating increased avidity, such as receptor clustering 
or  altered  receptor interaction with  the cytoskeleton, is 
unclear. However, while RGD peptide induced the activa- 
tion-dependent  LIBS1  epitope  on  etv133-overexpressing 
OV10, this was independent of IAP expression. Whatever 
the mechanism, these studies clearly demonstrate an im- 
portant distinction between bead binding  and  adhesion. 
Thus, studies using bead binding as a model for adhesion 
to a surface (Miyamoto et al.,  1995a,b) need to be inter- 
preted with some caution. 
The extent of Vn-bead binding is dependent on the lev- 
els of both lAP and av133 expression, but even increasing 
c~133 expression 10-fold did not make bead binding lAP in- 
dependent.  Previous work in K562 cells has  shown  that 
Vn-bead binding also requires expression of %  integrins 
(Blystone et al., 1994). Since Vn-bead binding is sensitive 
to  the  concentrations of both  lAP  and  ~[33  in  the  cell 
membrane, it is likely that bead binding requires a physical 
complex  between  IAP  and  the  integrin.  As  previously 
shown for platelets (Brown et al.,  1990), integrin 133 coim- 
munoprecipitates with lAP in OV10 transfectants. How- 
ever, under the conditions of the assay, most lAP on the 
cell surface is not  associated  with  133 integrin,  and  most 
etv[33 is not associated with lAP. Using the mild detergent 
conditions required to show coprecipitation, lAP is rela- 
tively poorly solubilized, whereas harsher conditions dis- 
rupt IAP-integrin association. It is clear, since lAP can be 
expressed on ceils in the absence of a~ integrins (Blystone 
et  al.,  1994),  and o~v integrins can be expressed without 
lAP in OV10, that transport to the plasma membrane does 
not require complex formation between these proteins. In- 
stead, the complex probably forms on the plasma mem- 
brane, presumably in equilibrium with free IAP and e~v133. 
The complex has ligand-binding properties distinct from 
free av[33. A  simple  explanation for the  requirement of 
IAP in %  integrin bead binding would be that IAP is nec- 
essary for generation of the high affinity form of the inte- 
grin. However, we found no evidence for any IAP-depen- 
dent  change  in  ligand  affinity, using  the  display  of the 
LIBS1 epitope as assay. This does not rule out the possibil- 
ity that a small but functionally important subset of C~v in- 
tegrin molecules are  affinity regulated by lAP, but it is 
more likely that lAP acts in some other way to alter the 
function of C~v integrins. It will be interesting and impor- 
tant to determine which of the integrin's functions in mi- 
gration, neovascularization, metastasis, etc. (Leavesley et 
al., 1992, 1993; Brooks et al., 1994; Filardo et al., 1995) are 
actually dependent on its association with lAP. 
OV10 cells express much more C~vl35 than av133 (Table 1). 
Since Vn-bead binding is dependent on IAP, and on K562 
cells (which express lAP), etv135 can bind Vn-beads in the 
absence of c~133 (Blystone et al., 1994), it is very likely that 
av135 also  interacts functionally with  lAP.  We could not 
coimmunoprecipitate lAP with c~135, but this may reflect 
only a  slightly lower interaction between the two mole- 
cules in detergent solution than between lAP and etvl33. 
Both  anti-J33 mAb  7G2  and  anti-etv[35 mAb  P1F6  com- 
pletely inhibit Vn-bead binding regardless of the relative 
amounts of av133 and av[35. Furthermore, P1F6 but not 7G2 
blocked Fn-bead binding. In contrast, P1F6 had no effect 
on adhesion to Vn (Fig. 3) or Fn (not shown). While the 
basis  of these  effects of av integrin  antibodies  on bead 
binding is unknown, they may reflect interintegrin signal- 
ing (cross talk) (Blystone et al., 1994, 1995). Alternatively, 
inhibition  may  reflect  clustering  of several  integrins  at 
sites of cell-bead contact, with resulting steric inhibition of 
binding by either mAb. However, lAP would reasonably 
be  expected to  be  present  in  such  an  aggregate,  and  a 
purely sterical inhibition is hard to reconcile with the lack 
of effect of the noninhibitory anti-lAP mAb 2D3. 
The  absence  of IAP  in  OV10  cells  allowed  the  first 
structure-function studies on IAP. These studies demon- 
strated that the amino-terminal IgV domain was necessary 
and sufficient for Vn-bead binding. The importance of the 
IgV domain of lAP for interaction with etv integrins is in- 
triguing because interactions between Ig family members 
and integrins are well-described mechanisms for cell-cell 
interaction  in  the  immune  system.  ICAM-1  interaction 
with  132 integrins (Diamond et al.,  1991;  Staunton et al., 
1990), PECAM-1 with C~v133 (Piali et al., 1995; Buckley et al., 
1996), VCAM-1  with a4131(Elices et al., 1990), and Mad- 
CAM with 0t4137 (Berlin et al., 1993; Briskin et al., 1996) all 
have roles in transendothelial migration of leukocytes. In 
contrast to these cell-cell adhesive interactions, the IAP- 
integrin interaction must involve an IgV domain on the 
same cell as the integrin, lAP interaction with %  integrins 
would represent an extension of the paradigm of Ig fam- 
ily-integrin binding to interactions between molecules on 
a single plasma membrane. 
The cell type-specific expression of different cytoplas- 
mic tail forms of lAP would suggest that this part of the 
molecule has a specific functional role. Also, the anti-lAP 
inhibitable inward calcium flux in endothelial cells spread- 
ing on Vn (Schwartz et al., 1993) makes the IAP multiply 
membrane-spanning  domain  a  potential candidate  for a 
channel.  Surprisingly, both these parts of the lAP mole- 
cule are dispensable for Vn-bead binding in our transfec- 
tion system. It is theoretically possible that a mutated form 
of lAP is expressed by OV10 and is able to interact with 
IAP-GPI  and  IAP-TM,  reconstituting  a  functional  but 
noncovalently  associated  lAP  molecule.  However,  we 
have been unable to detect in OV10 any lAP message by 
reverse transcriptase-PCR, any IAP-2 or IAP-4 cytoplas- 
mic tail by immunoblot or immunoprecipitation with spe- 
cific antisera, or any IAP Ig immunoglobulin domain with 
monoclonal and polyclonal anti-lAP antibodies by immu- 
noprecipitation or FACS  ® (not shown).  This makes  the 
existence of any mutant lAP protein in OV10 highly un- 
likely. More likely, while interaction with %  integrins is 
mediated by the IgV domain, other, as yet undefined func- 
tions of lAP require these other domains. 
Recently, lAP has been shown to be the receptor for the 
carboxy-terminal cell-binding domain of thrombospondin-1 
(TS-1) (Gao et al., 1996). TS-1 is a 450-kD trimeric matrix 
protein that, in  addition to the cell-binding domain, has 
several other cell- and matrix-interaction domains, includ- 
Lindberg et al. lntegrin-associated Protein  1321 ing a  RGD  sequence  capable  of ligating C~vl33. This sug- 
gests  the possibility that the Vn used may contain small 
amounts of TS-1, and that this contaminant is responsible 
for the lAP effect on Vn-bead binding. However, binding 
of beads coated with synthetic RGD peptides and analogs 
is also inhibited by anti-lAP (Gresham et al., 1989, 1992; 
Brown  et  al.,  1990),  ruling out the  possibility  that TS-1 
contamination of Vn is the reason for the IAP dependence. 
In summary, this work is the first to show that any spe- 
cific  function of av  requires  lAP.  Surprisingly,  Vn-bead 
binding by tXv integrins, which is IAP dependent in OV10 
cells,  requires only a  membrane-associated  IAP  IgV  do- 
main, and the IgV domain is sufficient to mediate coimmu- 
noprecipitation of IAP  with etv~  3. This suggests  that the 
IAP--avl33  complex  represents  an  extension  of the  inte- 
grin-Ig family adhesive interactions to molecules on a sin- 
gle plasma membrane for the purpose of modulating in- 
tegrin  function.  The  structural  details  and  biological 
consequences of this modulation, as well as the functions 
of the more complex membrane-spanning and cytoplasmic 
domains of lAP, remain to be determined. 
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